Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630 in Adults with Asthma on Medium-to-High Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists

The primary objective of this study is to evaluate the **safety**, **pharmacokinetics**, and **pharmacodynamics** of AZD8630 when administered once daily via inhalation over a period of two weeks in adults diagnosed with **asthma** who are currently on medium-to-high dose inhaled corticosteroids and long-acting beta-agonists. This assessment is clinically relevant as it aims to determine the potential therapeutic benefits and safety profile of AZD8630, which could offer an alternative treatment option for asthma management.

The clinical trial involves participants diagnosed with **asthma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial population selection criteria and the total number of participants have not been disclosed by the sponsor. The study includes a vulnerable population, indicating that special considerations may be necessary for their participation. No specific lifestyle considerations such as diet, physical activity, or habits have been provided. The sponsor has not given detailed information regarding the key inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the **safety**, pharmacokinetics, and pharmacodynamics of AZD8630, administered once daily via inhalation for a duration of two weeks in adults diagnosed with **asthma**. The study is structured as a Phase 3 trial, which is a critical stage in the clinical research process, focusing on the efficacy and monitoring of adverse reactions in a larger patient population. The trial is expected to commence recruitment on November 1, 2024, and is anticipated to conclude by May 5, 2025.

The trial will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to either the treatment group receiving AZD8630 or a control group, with neither the participants nor the investigators aware of the group assignments, thus minimizing bias. The study will include several key visits: an initial screening visit to assess eligibility based on predefined criteria, followed by regular follow-up visits to monitor the participants' response to the treatment and any potential side effects. The end-of-study visit will be conducted to gather final data and ensure the well-being of the participants post-treatment.

Participant involvement in the study is expected to last approximately two weeks, corresponding to the treatment duration. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial's design and procedures are meticulously crafted to uphold the highest standards of clinical research, ensuring the collection of robust and meaningful data to advance the understanding of AZD8630's therapeutic potential in managing asthma.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on November 1, 2024, with an estimated end date of May 5, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured schedule for measuring, collecting, and analyzing these efficacy parameters, adhering to the standards expected in a Phase 3 clinical trial. The methods and tools for efficacy assessment are not specified in the available information. The trial will proceed according to the outlined timeline, ensuring that data collection and analysis are conducted systematically to determine the efficacy of the intervention under investigation.